BPG is committed to discovery and dissemination of knowledge
Observational Study
©The Author(s) 2021.
World J Clin Oncol. Jan 24, 2021; 12(1): 13-30
Published online Jan 24, 2021. doi: 10.5306/wjco.v12.i1.13
Figure 7
Figure 7 Protein expression status of C-C chemokine ligand 2/vascular endothelial growth factor/epidermal growth factor of two cell population from tumor sample and circulating tumor cells in patient 11 affected with meningioma. C-C chemokine ligand 2 (CCL2), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF) are conjugated with fluorescein isothiocyanate, R-phycoerythrin, and phycoerythrin–indodicarbocyanine, respectively, in patient number 3. A: Vascular images accompanied by the partial tumor section [1: Merged of 4′,6-diamidino-2-phenylindole (DAPI)/CCL2; 2: Merged of DAPI/VEGF; 3: Merged of DAPI/ EGF; 4: Co-expression of CCL2/EGF/VEGF; 5: Co-expression of DAPI/CCL2/VEGF/EGF; 6: A cropped section of 5]; B: Image of a tumor section reflecting of the Co-expression of CCL2/VEGF/EGF; C [1:DAPI/CCL2/VEGF/EGF; 2:CCL2/VEGF/EGF]: Illustrates the CTCs in the blood sample of the same patient. The arrows are indicative of expression status in tumor cells, in vasculature, and the microvesicles.


Write to the Help Desk